HAC (Russian)
RSCI (Russian)
Ulrichsweb (Ulrich’s Periodicals Directory)
Scientific Indexing Services

Back pain in young patients

DOI: https://doi.org/10.29296/25877305-2023-01-15

I. Romanov(1), O. Shavlovskaya(2), I. Bokova(3)
1-«MD-Clinic» Network of Medical centers, Moscow
2-International University of Restorative Medicine, Moscow
3-Sechenov First Moscow State Medical University of the Ministry of Health
of Russia (Sechenov University)

Osteoarthritis (OA) of the facet joint (FJ) plays a significant genesis role of chronic lower back pain (cLBP) in 15–41%. OA FJ of lumbar spine occurs in 24–82% of younger people than 40 years. It has been shown that the ingestion of the "back pain" symptom at a young age in the subsequent (after 10–15 years) leads to the formation of cLBP, with a recurrent course, while OA FJ is noted in the overwhelming number of patients studied. An important aspect in the tactics choice of back pain in young patients treatment is the chronization prevention and pain syndrome relapses. In LBP treatment of against the background of OA FJ, it is recommended to use standard scheme therapy: at the first stage – injectable and oral nonsteroidal anti-inflammatory drugs (NSAIDs), muscle relaxants, B vitamins, as well as injectable Symptomatic Slow-Acting Drugs for Osteoarthritis (SYSADOA) – chondroitin sulfate (CS), glucosamine sulfate (GS), undenatured collagen II type (UC-II), as well as their combinations; at the second stage – oral SYSADOA (CS, GS, UC-II, as well as their combinations) and topical NSAIDs. SYSADOA have symptom- and structural-modifying effects. As a promising direction of OA therapy, the use of drugs with already proven efficacy containing CS, GS, in combination with a new molecule – UC II is considered.

lower back pain
facet joint
facet syndrome
young age
symptomatic slow-acting drugs.

  1. Yakhno N.N., Kukushkin M.L., Churyukanov M.V. et al. The results of the open multicenter study «MERIDIAN» to assess the prevalence of pain syndromes in outpatient practice and therapeutic preferences of doctors. Rossiiskii Zhurnal Boli. 2012; 3-4 (36-37): 10–4 (in Russ.).
  2. Shostak N.A., Pravduk N.G., Klimenko A.A. et al. Dorsalgia in young: peculiarities and approaches to treatment. Lechebnoe delo. 2009; 1: 45–50 (in Russ.).
  3. Pravdyuk N.G., Shostak N.A., Novikova A.V. Back pain in young people: clinical and instrumental features considering long-term observations. Lechebnoe delo. 2021; 3: 81–93 (in Russ.). DOI: 10.24412/2071-5315-2021-12363
  4. Tkachev A.M., Gordeeva I.E., Epifanov A.V. Facet syndrome in the clinical picture of dorsopathies. Farmateka. 2021; 28 (13): 31–43 (in Russ.). DOI: 10.18565/pharmateca.2021.13.31-43
  5. Davydov O.S. Facet joint osteoarthritis as a component of non-specific low back pain. Neurology, Neuropsychiatry, Psychosomatics. 2019; 11 (suppl.2): 76–82 (in Russ.). DOI: 10.14412/2074-2711-2019-2S-76-82
  6. Du R., Xu G., Bai X. et al. Facet joint syndrome: pathophysiology, diagnosis, and treatment. J Pain Res. 2022; 15: 3689–710. DOI: 10.2147/JPR.S389602
  7. Shpagin M.V., Yarikov A.V., Nazmeev I.A. et al. The experience of denervation of facet joints in the lumbar spine. Hirurgiâ pozvonočnika = Spine Surgery. 2019; 16 (1): 57–62 (in Russ.). DOI: 10.14531/ss2019.1.57-62
  8. Meloncelli S., Germani G., Urti I. et al. Endoscopic radiofrequency facet joint treatment in patients with low back pain: technique and long-term results. A prospective cohort study. Ther Adv Musculoskelet Dis. 2020; 12: 1759720X20958979. DOI: 10.1177/1759720X20958979
  9. Shostak N.A., Pravdyuk N.G., Novikova A.V. et al. Back pain in young people: focus on spondyloarthritis (clinical observation). Poliklinika. 2020; 2: 22–8 (in Russ.).
  10. Jain S., Shetty G., Munje P. et al. Gender-based variations in trunk motion and isometric strength in young adults with low back pain: a prospective case-control study. Rev Bras Ortop. 2022; 57 (3): 392–401. DOI: 10.1055/s-0041-1736199
  11. Rachin A.P., Azimova Yu.E., Nuvakhova M.B. et al. Back pain: diagnostic algorithm and tactics in therapy. RMJ. 2015; 26 (23): 1532–7 (in Russ.).
  12. Putilina M.V., Ivanova M.P., Petrikeeva A.E. et al. Difficulties in diagnosing sacroiliitis in young patients. Zhurnal Nevrologii i Psikhiatrii imeni S.S. Korsakova. 2020; 120 (8): 117–26 (in Russ.). DOI: 10.17116/jnevro2020120081117
  13. Nepovinnych L.A., Solodovnik E.M. Problem of overweight among young people. Scientific format. 2019; 1 (1): 97–103 (in Russ.).
  14. Shkrebko A.N., Glushakov A.N. Clinical effi cacy evaluation of weight loss methods in gonarthrosis treatment in women. Sports medicine: research and practice. 2020; 10 (1): 21–9 (in Russ.). DOI: 10.17238/ISSN2223-2524.2020.1.21
  15. Ignatova A.V. Experience of using the drug Chondroguard as part of medical and drug blockades in the treatment of facet syndrome and sacroiliac joint dysfunction in outpatient settings. RMJ. 2013; 21 (10): 524–6 (in Russ.).
  16. Price M.R., Cupler Z.A., Hawk C. et al. Systematic review of guideline-recommended medications prescribed for treatment of low back pain. Chiropr Man Therap. 2022; 30 (1): 26. DOI: 10.1186/s12998-022-00435-3
  17. Gianola S., Bargeri S., Del Castillo G. et al. Effectiveness of treatment for acute and subacute mechanical non-specific low back pain: a systematic review with network meta-analysis. Br J Sports Med. 2022; 56 (1): 41–50. DOI: 10.1136/bjsports-2020-103596
  18. Shavlovskaya O.A., Romanov I.D., Prokofyeva Yu.S. Experience with chondroitin sulfate in the combination therapy of lower back pain. Neurology, Neuropsychiatry, Psychosomatics. 2020; 12 (3): 75–81 (in Russ.). DOI: 10.14412/2074-2711-2020-3-75-81
  19. Conrozier T., Lohse T. Glucosamine as a treatment for osteoarthritis: what if it’s true? Front Pharmacol. 2022; 13: 820971. DOI: 10.3389/fphar.2022.820971
  20. Gromova O.A., Torshin I.Yu., Lila A.M. About the use of chondroitin sulfate, glucosamine sulfate and undenatured type II collagen for back and limb pain and osteoarthritis. Neurology, Neuropsychiatry, Psychosomatics. 2022; 14 (6): 122–30 (in Russ.). DOI: 10.14412/2074-2711-2022-6-122-130
  21. Gromova О.А., Lila А.М., Torshin I.Yu. et al. Application of chondroprotective agents to inhibit osteodestructive processes in the subchondral bone in patients with osteoarthritis. Farmakoekonomika. Modern Pharmacoeconomics and Pharmacoepidemiology. 2022; 15 (1): 107–18 (in Russ.). DOI: 10.17749/2070-4909/farmakoekonomika.2022.126
  22. Sarvilina I.V., Minasov T.B., Lila A.M. et al. On the efficacy of the parenteral form of highly purified chondroitin sulfate in the mode of perioperative preparation for total knee arthroplasty. RMJ. 2022; 7: 7–16 (in Russ.).
  23. Minasov T.B., Lila A.M., Nazarenko A.G. et al. Morphological reflection of highly purified chondroitin sulfate action in patients with decompensated form of knee osteoarthritis. Modern Rheumatology Journal. 2022; 16 (6): 55–63 (in Russ.). DOI: 10.14412/1996-7012-2022-6-55-63
  24. Nagaoka I., Tsuruta A., Yoshimura M. Chondroprotective action of glucosamine, a chitosan monomer, on the joint health of athletes. Int J Biol Macromol. 2019; 132: 795–800. DOI: 10.1016/j.ijbiomac.2019.03.234
  25. Shavlovskaya O.A., Gromova O.A., Torshin I.Yu. Points of undenatured type II collagen application in musculoskeletal pain syndromes treatment. Zhurnal Nevrologii i Psikhiatrii imeni S.S. Korsakova. 2022; 122 (11): 40–5 (in Russ.). DOI: 10.17116/jnevro202212211140
  26. Lugo J.P., Saiyed Z.M., Lau F.C. et al. Undenatured type II collagen (UC-II) for joint support: a randomized, double-blind, placebo-controlled study in healthy volunteers. J Int Soc Sports Nutr. 2013; 10 (1): 48. DOI: 10.1186/1550-2783-10-48
  27. Kirmse M., Oertzen-Hagemann V., de Marees M. et al. Prolonged collagen peptide supplementation and resistance exercise training affects body composition in recreationally active men. Nutrients. 2019; 11 (5): 1154. DOI: 10.3390/nu11051154
  28. Grooten W.J.A., Bostrom C., Dedering A. et al. Summarizing the effects of different exercise types in chronic low back pain – a systematic review of systematic reviews. BMC Musculoskelet Disord. 2022; 23: 801. DOI: 10.1186/s12891-022-05722-x